At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Pravastatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 20, 2019·Updated Sep 18, 2023
In Brief
A Phase 2 clinical trial evaluating Pravastatin, Rifafour, and 1 other intervention for Tuberculosis and Pulmonary Tuberculosis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of pravastatin adjunctive therapy when combined with the standard tuberculosis (TB) treatment regimen in adults with TB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis, Pulmonary Tuberculosis
CountriesSouth Africa
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartFeb 2020
Primary CompletionMay 2022
Study CompletionDec 2022
TodayJul 2026
First PostedMar 20, 2019
Enrollment StartFeb 21, 2020
Primary CompletionMay 12, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.3 years ago
Interventions
Pravastatindrug
Tablets, administered orally
Rifafourdrug
Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
Vitamin B6dietary
Administered orally.